Open Nav

Please submit your session questions in advance at

Verona Pharma

  • Piers Morgan, Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine, is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that is designed to act as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, the nebulized formulation of ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva®), compared with such bronchodilators administered as a single agent.

  • Date:Tuesday, February 12
  • Time:2:30 PM - 2:45 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23560
  • Goal for Presentation:Raise profile for Phase 2 COPD candidate
  • Company
  • Company HQ City:London
  • Company HQ Country:United Kingdom
  • Market Cap:$98 million
  • Ticker:VRNA
  • Exchange:nasdaq
  • CEO/Top Company Official:Jan-Anders Karlsson, CEO
  • Main Therapeutic Focus:Respiratory
  • Lead Product in Development:Ensifentrine (RPL 554)
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Dual listed AIM:VRP and NASDAQ:VRNA
Piers Morgan
Verona Pharma